Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 2, 2009, Pages 168-174

  Alibhai, Shabbir M H ^a,b,d,e   Leach, Marc ^a   Gupta, Vikas ^c,d   Tomlinson, George A ^a,f   Brandwein, Joseph M ^c,d   Saiz, Fernando Suarez ^c   Minden, Mark D ^c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Mathematics and Computer Science   (Canada)

^e Health Policy Management and Evaluation   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute myeloid leukemia; Aged; Functional status; Quality of life; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER REGRESSION; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL ARTICLE; COGNITION; DRUG MEGADOSE; EMOTIONAL STABILITY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; SOCIAL STATUS;

AGED; AGED, 80 AND OVER; COGNITION; EMOTIONS; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; REMISSION INDUCTION;

EID: 58149229323     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.07.015     Document Type: Review

References (16)

1. Sekeres M.A., Stone R.M., Zahrieh D., et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18 4 (2004) 809-816
2. Alibhai S.M.H., Leach M., Kermalli H., et al. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Critical Reviews in Oncology/Hematology 64 (2007) 19-30
3. Alibhai S.M., Leach M., Kowgier M.E., Tomlinson G.A., Brandwein J.M., and Minden M.D. Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status. Leukemia 21 4 (2007) 845-848
4. Curt G.A., Breitbart W., Cella D., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5 5 (2000) 353-360
5. Given C.W., Given B., Azzouz F., Kozachik S., and Stommel M. Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients. Journal of Pain and Symptom Management 21 6 (2001) 456-466
6. Iop A., Manfredi A.M., and Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Annals of Oncology 15 5 (2004) 712-720
7. Morrow G.R., Andrews P.L., Hickok J.T., Roscoe J.A., and Matteson S. Fatigue associated with cancer and its treatment. Supportive Care in Cancer 10 5 (2002) 389-398
8. Gupta V., Chun K., Yi Q.L., et al. Disease biology rather than age is the most important determinant of survival of patients > or =60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 103 10 (2005) 2082-2090
9. Gardin C., Turlure P., Fagot T., et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109 12 (2007) 5129-5135
10. Koistinen P., Raty R., Itala M., et al. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. European Journal of Haematology 78 6 (2007) 477-486
11. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 85 5 (1993) 365-376
12. Osoba D., Rodrigues G., Myles J., Zee B., and Pater J. Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology 16 1 (1998) 139-144
13. Cella D., Eton D.T., Lai J.S., Peterman A.H., and Merkel D.E. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management 24 6 (2002) 547-561
14. Jacobsen P.B. Assessment of fatigue in cancer patients. Journal of the National Cancer Institute Monographs 32 (2004) 93-97
15. Jean-Pierre P., Figueroa-Moseley C.D., Kohli S., Fiscella K., Palesh O.G., and Morrow G.R. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12 Suppl 1 (2007) 11-21
16. Menzin J., Lang K., Earle C.C., Kerney D., and Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Archives of Internal Medicine 162 14 (2002) 1597-1603